Results 201 to 210 of about 274,980 (287)
1,1‐Disubstituted Vinylbromides: Versatile Building Blocks for the Synthesis of Nitrogen‐Containing Heterocycles
European Journal of Organic Chemistry, EarlyView.1,1‐Disubstituted vinylbromides are key intermediates for constructing nitrogen‐containing heterocycles. This review provides an overview of the synthetic applications of 1,1‐disubstituted vinylbromides and summarizes recent developments in reaction methodologies, mechanistic insights, and the structural diversity of N‐heterocyclic compounds accessible Anne Westermeyer, Jun Fang, Chonghuo Liu, Guillaume Lefèvre, Gérard Guillamot, Phannarath Phansavath, Virginie Ratovelomanana‐Vidal +6 morewiley +1 more sourceA plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. [PDF]
Future OncolJohnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. +20 moreeuropepmc +1 more sourceDefining the end point of status epilepticus: A scoping review and framework for standardization
Epilepsia, EarlyView.Abstract
Status epilepticus (SE) is a life‐threatening neurological emergency with consensus‐driven definitions for onset but no standardized criteria for its end point. This gap creates uncertainty in research and clinical practice. We conducted a scoping review to evaluate how end points have been defined in SE research and to identify key areas of ...Fawad A. Khan, Margaret T. Gopaul, Samuel L. Carter, Anil Chimakurthy, Summer Skelton, Lawrence J. Hirsch, Eugen Trinka +6 morewiley +1 more sourceLong-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial. [PDF]
Blood Cancer JUreshino H, Murai K, Kumagai T, Mino T, Nishiwaki K, Wakita S, Takeoka T, Mita M, Yoshida C, Uoshima N, Fukushima T, Kuroda J, Kondo T, Chiba M, Miyazaki T, Io K, Ueda T, Ono T, Usuki K, Yamauchi T, Fujimaki K, Ikezoe T, Kawaguchi A, Kimura S. +23 moreeuropepmc +1 more sourceAnalysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project. [PDF]
ESMO OpenSánchez-Bayona R, de Nicolás-Hernández J, Saura C, Gion M, Cejalvo JM, Llabrés E, Cortés J, Falcón A, Pernas S, López de Sa A, Vidal M, Hinojo C, Curiel T, Cruz J, Martínez V, Cantos B, Echarri MJ, Gallegos I, Bueno C, Vargas AM, Escrivá-de-Romaní S, Fullana B, Cobos MA, Arenas A, Joval-Ramentol L, Ortiz P, Pascual T, Valdivia C, Villacampa G, Ciruelos E, Rodriguez-Antona C. +30 moreeuropepmc +1 more sourceA phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox–Gastaut syndrome
Epilepsia, EarlyView.Soticlestat as adjunctive therapy for Lennox–Gastaut syndrome. Abstract Objective
There remains a need for new treatments for Lennox–Gastaut syndrome (LGS), a developmental and epileptic encephalopathy with a heterogenous patient population that often requires polytherapy. The phase 3, randomized SKYWAY study (NCT04938427) investigated the efficacy and Renzo Guerrini, Eric D. Marsh, Wei‐Ping Liao, Katsumi Imai, Ruzica Kravljanac, Anna Altmann, Cecil D. Hahn, Stéphane Auvin, Jimmy Schiemann, Yasir Khan, Pranab Mitra, Sarah I. Sheikh, Philipp von Rosenstiel, Mahnaz Asgharnejad, Dennis Dlugos, Venkatesha Murthy +15 morewiley +1 more sourceWhat is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation. [PDF]
Ann HematolKrause SW, Bethge W, Bug G, Elmaagacli A, Jost E, Klein SA, Kobbe G, Kraus S, Krüger WH, Luft T, Müller LP, Schäfer-Eckart K, Schetelig J, Steiner N, Stelljes M, Tischer J, Winkler J, Wolff D, Wortmann F, Röllig C. +19 moreeuropepmc +1 more sourceA consensus roadmap for post‐traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials
Epilepsia, EarlyView.Abstract
Understanding the mechanisms underlying post‐traumatic epilepsy (PTE) following traumatic brain injury (TBI), and developing strategies to prevent or modify its progression, has been the focus of large collaborative efforts within the epilepsy and TBI research communities for over a decade.Elisa R. Zanier, Ilaria Lisi, Elaine K. O'Loughlin, Federico Moro, Edilberto Amorim, David L. Brody, Daniel J. Correa, Dominique Duncan, Pavel Klein, Firas H. Kobeissy, Wolfgang Löscher, Edward J. Needham, Asla Pitkänen, Mary Jo Pugh, Jack Somers, Annamaria Vezzani, Amy K. Wagner, Laura S. Lubbers, International Conference on PTE Attendees, Denes Agoston, Edilberto Amorim, Sneha Anand, Hibah Awwad, Ginevra Bayon, Naima Belhachemi, Akash Bera, Costanza Bertani, Guido Bertolini, David L. Brody, Serena Brusatori, Francesca Buffelli, Aurora Chiapperini, Mara Chioccola, Severn Churn, Daniel J. Correa, Ramon Diaz‐Arrastia, Chris Dulla, Dominique Duncan, Chiara Ferlito, Aristea Galanopoulou, Angela Galic, Heidi Matos Galicia, Bin Gu, William Haskins, Victoria Johnson, Nigel Jones, Lowie Joseph, Pavel Klein, Firas Kobaissy, Ilaria Lisi, David Loane, Luther Loose, Laura S. Lubbers, Wolfgang Löscher, Edoardo Mazzone, Melissa Miller, Federico Moro, Edward J. Needham, Irma Wati Ngadimon, Terence O’Brien, Elaine K. O’Loughlin, Asla Pitkanen, Mary Jo Pugh, Teresa Giovanna Ravizza, Giuseppe Remuzzi, Massimo Rizzi, Rossella Di Sapia, Tawfeeq Shekh‐Ahmad, Doug Smith, Jack Somers, Kevin Staley, Francesca Tribuzio, Alexandra Ulyanova, Gloria Vegliante, Annamaria Vezzani, Joost Wagenaar, Amy K. Wagner, Kevin W. Wang, Justin Weppner, Peter J. West, Karen Wilcox, John Wolf, Elisa R. Zanier +82 morewiley +1 more source